Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00160693
Status:
COMPLETED
Last Update Posted:
2018-08-01
First Post:
2005-09-06
Brief Title:
Open Label Long-Term Safety Study of Certolizumab Pegol CZP for Patients With Rheumatoid Arthritis
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
A Phase III Multicenter Open-Label Long-Term Study to Assess the Safety and Tolerability of CDP870 400 mg Subcutaneously Every 4 Weeks in Subjects With Rheumatoid Arthritis
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03559686
Has Expanded Access, NCT# Status:
AVAILABLE
Acronym:
None
Brief Summary:
The primary purpose of this study is to obtain long-term safety data with CZP in patients with Rheumatoid Arthritis RA Additional objectives are to assess the dose and type of Arthritis medications utilized by patients and to assess the long-term impact of CZP on physical function Treatment will continue up to approval of a marketing application for this product
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-002617-21 | EUDRACT_NUMBER | None | None |